Biogen
Venture capital · Cambridge, Massachusetts, United States
Portfolio collected from the firm’s website, last checked Jun 28, 2026.Raises and exits come from each company’s own SEC and company records.
6Deep-tech portfolio2 active
4Portfolio exitsAcquired or listed
0Raises, 12 monthsLatest: Solid Biosciences
12Co-investorsShare a portfolio company
Portfolio · 6 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Dayra Therapeutics | Biotech | Active | — | — |
| Newleos | Biotech | Active | — | — |
| Solid Biosciences | Biotech | Public | Dec 9, 2022 | $109.2M |
| Vigil Neuroscience | Biotech | Acquired | Aug 29, 2022 | $195.0M |
| Ra Pharmaceuticals | Biotech | Acquired | Jul 23, 2015 | $39.6M |
| Sangamo Therapeutics | Biotech | Public | — | — |
Peer ranks
Portfolio size#67
Portfolio exits#49
Raises, 12 months#88
Co-investors#150
Co-investors
- Atlas VentureVenture capital2 shared
- Cormorant Asset ManagementVenture capital1 shared
- F-Prime CapitalVenture capital1 shared
- GenzymeVenture capital1 shared
- Goldman Sachs AlternativesVenture capital1 shared
- LifeSci Venture PartnersVenture capital1 shared
- Longitude CapitalVenture capital1 shared
- Longwood FundVenture capital1 shared
- Novo HoldingsVenture capital1 shared
- RA CapitalVenture capital1 shared
Sectors
- Biotech6
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.